Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement

NCT03047681 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-02-09

No results posted yet for this study

Summary

An association between mast cells and outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) has not been studied to our knowledge. We aim to characterize tryptase levels dynamics during TAVR; Demonstrate whether tryptase level post-TAVR can be used as a prognostic marker.

Conditions

  • Transcatheter Aortic Valve Implantation Prosnosis and Complications

Interventions

DIAGNOSTIC_TEST

venous blood withdrawl

patients will be asked for a venous blood sample

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-08-01
Completion
2017-12-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03047681 on ClinicalTrials.gov